The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

While issuing its RSV warning mandate on Tuesday, the FDA added that the benefits of vaccination with Abrysvo and Arexvy “continue to outweigh their risks.” During an FDA advisory panel ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...